These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 30119147)

  • 1. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic treatment strategies for community-acquired pneumonia in adults.
    Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
    N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
    Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
    Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
    Lee JH; Kim HJ; Kim YH
    J Korean Med Sci; 2017 Jan; 32(1):77-84. PubMed ID: 27914135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study.
    Reeves SD; Hartmann AP; Tedder AC; Juang PA; Hofer M; Kollef MH; Micek ST; Betthauser KD
    Clin Ther; 2024 Apr; 46(4):338-344. PubMed ID: 38403509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
    Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of the combination and quinolone therapy in community acquired pneumonia].
    Kılıç Soylar Ö; Kılınç O; Ellidokuz H
    Tuberk Toraks; 2015 Sep; 63(3):165-9. PubMed ID: 26523897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
    Raz-Pasteur A; Shasha D; Paul M
    Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
    Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
    J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
    Mortensen EM; Restrepo MI; Anzueto A; Pugh J
    Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy.
    van Werkhoven CH; van de Garde EMW; Oosterheert JJ; Postma DF; Bonten MJM
    Respir Med; 2017 Aug; 129():145-151. PubMed ID: 28732822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
    Williams DJ; Edwards KM; Self WH; Zhu Y; Arnold SR; McCullers JA; Ampofo K; Pavia AT; Anderson EJ; Hicks LA; Bramley AM; Jain S; Grijalva CG
    JAMA Pediatr; 2017 Dec; 171(12):1184-1191. PubMed ID: 29084336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dilemma of monotherapy or combination therapy in community-acquired pneumonia.
    Vardakas KZ; Trigkidis KK; Apiranthiti KN; Falagas ME
    Eur J Clin Invest; 2017 Dec; 47(12):. PubMed ID: 29027205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
    van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
    BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia.
    Wilson BZ; Anzueto A; Restrepo MI; Pugh MJ; Mortensen EM
    Crit Care Med; 2012 Aug; 40(8):2310-4. PubMed ID: 22622401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
    Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
    BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
    File TM
    J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
    Ito A; Ishida T; Tachibana H; Nakanishi Y; Tokioka F; Yamazaki A; Washio Y; Irie H; Otake T
    J Infect Chemother; 2021 Oct; 27(10):1447-1453. PubMed ID: 34147355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.